about
The management of glaucoma and intraocular hypertension: current approaches and recent advancesRational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.Recent advances in pharmacotherapy of glaucomaNanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.Mini drug pump for ophthalmic use.Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis.Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension.Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.Crystallins are regulated biomarkers for monitoring topical therapy of glaucomatous optic neuropathy.Short- and long-term safety of glaucoma drugs.Note: A gel based imaging technique of the iridocorneal angle for evaluation of angle-closure glaucoma.Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamideAn evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension.Marine AChE inhibitors isolated from Geodia barretti: natural compounds and their synthetic analogs.Preclinical imaging of iridocorneal angle and fundus using a modified integrated flexible handheld probe.Topical treatment of glaucoma: established and emerging pharmacology.Application of encapsulated cell technology for retinal degenerative diseases.Ocular fibroblast types differ in their mRNA profiles--implications for fibrosis prevention after aqueous shunt implantationPharmacogenetics of ophthalmic topical beta-blockers.Recent perspectives in ocular drug delivery.Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.Metabolism of ophthalmic timolol: new aspects of an old drug.Novel drug delivery systems for glaucoma.A review of the use of latanoprost for glaucoma since its launch.Antiglaucoma pharmacotherapy.Nature: a substantial source of auspicious substances with acetylcholinesterase inhibitory action.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia.2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressureEfficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension.Emerging trabecular outflow drugs.Carbonic anhydrase inhibitors: synthesis and inhibition against isozymes I, II and IV of topically acting antiglaucoma sulfonamides incorporating cis-5-norbornene-endo-3-carboxy-2-carboxamido moieties.Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test.Poly (epsilon-caprolactone) microparticles containing Levobunolol HCl prepared by a multiple emulsion (W/O/W) solvent evaporation technique: effects of some formulation parameters on microparticle characteristics.Formulation and ex vivo-in vivo evaluation of pH-triggered brimonidine tartrate in situ gel for the glaucoma treatment using application of 32 factorial design.Glaucoma-Intraocular Pressure Reduction.
P2860
Q22305849-2387D67A-DC99-4CBC-B2BD-FC6B102E81E4Q33492373-0E28F260-3188-4A62-A5E4-CEE5F98A78AEQ33521178-D17D3125-DD29-4223-97C8-744D4919BC00Q33573405-D0AB3660-9560-40D2-AA7C-58A17452EB09Q33623415-2748AF77-7F41-4206-B553-90A7436AB94EQ33669278-CF1306CB-8EA9-4F11-A005-9A1B4A323351Q33996251-413C1AE4-46D1-435E-9CFA-D59E04C19AB9Q34511234-D9FF6A28-35F3-4114-A49F-3AD88C8C2E44Q34611288-F24A3105-EAFD-4245-83F5-5581BC9F49B8Q35194520-61F4837E-C087-4DEC-9FCB-8B01735341FEQ35199741-0A506825-9771-4A1B-B4A6-AD6212C4A1DCQ35590963-35B2C050-0500-4E37-B77D-198567CFEEE3Q35753429-A47E2E42-59E5-458D-8D2D-5BEA33B5E8BCQ35875939-29C70F90-B1A6-4D1C-BCE6-5426CEC6FDE8Q36348105-790CEC64-4785-47B8-AF17-74CEBB4E9705Q36365495-BACE84D5-E46D-454D-9F38-E5FC81518F06Q36521847-93BFEA65-F219-4BAF-8154-CF28261D153AQ36954775-2AA86B5C-2F44-4C76-82AD-37872BB5AEE2Q37116485-52974464-1247-4C6C-BDFE-6C47B63B00CFQ37256549-A2866BBD-9198-45D3-81F5-785DB4AD33D4Q37716010-4DB0CC53-D0CF-4D71-B472-233B789E8125Q37850837-D8A63902-41BE-43F3-9447-E027B40CF479Q37862989-1E1A4559-DE7A-4EB6-93CC-B7ED765D1D3BQ37986149-549974A7-33C3-410B-8EEA-2E77E80F5B23Q38050769-A80CCBDE-3645-4BE0-8A8C-DBC75A61C6DEQ38175019-6AF9235D-33FB-4230-9C26-0800FD927272Q38584194-E3131E90-F2AE-443D-BE20-02914FDC8676Q39096490-C13F43A1-CDAE-4D4E-8002-5F8F9A54F538Q39722931-35F0AE7A-3D69-4929-AA5C-8F03C587F714Q41953198-A75F9894-7693-40B1-8F6C-9C202313A9CFQ42344015-EAED762F-5D17-4222-987F-16FE4D0DBD73Q43600738-6ADEA9F7-15C2-48BF-8F0C-CFDC8BB3599DQ44024289-4702E855-8DCB-45B4-8A33-46629A20D8E0Q46496080-710401AF-D7E9-4789-BADB-B039133108F3Q47329132-957FEA78-E983-4174-B74B-93024727ACE2Q53555670-E5DD9FEA-333C-4534-B9D8-A69CCA65030E
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacological therapy for glaucoma: a review.
@ast
Pharmacological therapy for glaucoma: a review.
@en
type
label
Pharmacological therapy for glaucoma: a review.
@ast
Pharmacological therapy for glaucoma: a review.
@en
prefLabel
Pharmacological therapy for glaucoma: a review.
@ast
Pharmacological therapy for glaucoma: a review.
@en
P1433
P1476
Pharmacological therapy for glaucoma: a review.
@en
P2093
P304
P356
10.2165/00003495-200059030-00003
P577
2000-03-01T00:00:00Z
P5875
P6179
1013247114